S. Baker

Increased expression of RUNX3 inhibits normal human myeloid development

A. Gilkes, R. Darley, A. Tonks, 2022, Leukemia.

Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

A. Williamson, A. Whetton, M. Doyle, 2019, Leukemia.

Increased expression of RUNX3 inhibits normal human myeloid development

A. Gilkes, R. Darley, A. Tonks, 2022, Leukemia.

Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo

A. Gilkes, S. Knapper, M. Wong, 2020, British journal of haematology.

RUNX3 overexpression inhibits normal human erythroid development

A. Gilkes, R. Darley, A. Tonks, 2022, Scientific Reports.

E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia

M. Caligiuri, I. Park, S. Baker, 2017, Leukemia.